Sonneveld MJ, et al. - In patients treated with nucleo(s)tide analogue (NUC) therapy, researchers examined the predictive ability of hepatitis B core-related antigen (HBcrAg) levels for sustained hepatitis B e antigen (HBeAg) seroconversion. HBeAg-positive patients treated with NUCs were assessed for a minimum of 6 months. Outcomes of this study suggest a greater probability of HBeAg seroconversion for patients with lower baseline HBcrAg levels. However, there appeared a strong correlation of HBcrAg with other important factors, and in multivariate analysis, the correlation of HBcrAg with HBeAg seroconversion did not endure. Therefore, there is little additive information offered by HBcrAg quantification at baseline in these patients.